BMI1 and myelodysplastic syndrome: Thus, one can easily reason that the aberrant BMI1 levels inevitably disturb the gene expression profile of the haematopoietic stem cell, which may act sequentially or synergically with the existing genetic changes to promote malignant myeloid transformation in both MDS and CML.